

Semaglutide and tirzepatide are the two prescription medications people in Los Angeles ask about most when the subject is injectable weight management. They are not the same drug. They do not act on the same receptors, their approved uses do not fully overlap, and only one clinical trial has compared them directly at maximum tolerated dose. Most of what circulates online skips all three of those points.
This article sets out what each medication is, which uses the FDA has approved, what that one head-to-head trial measured, and what each label warns about. It is written for someone deciding whether to raise either medication with a physician. It is not a recommendation of one over the other. Which medication suits a particular person, or whether either is appropriate at all, depends on medical history, current prescriptions, other conditions, and what a clinician finds at an evaluation.
Semaglutide is a GLP-1 receptor agonist. It acts on one receptor, the receptor for glucagon-like peptide-1. It is sold under the brand name Wegovy for weight reduction and under the brand name Ozempic for glycemic control in type 2 diabetes.
Tirzepatide acts on two receptors: GLP-1 and GIP, the receptor for glucose-dependent insulinotropic polypeptide. It is sold as Zepbound for weight reduction and as Mounjaro for type 2 diabetes. That second receptor is the mechanical difference between the two drugs, and it is the reason researchers expected different results rather than identical ones.
Both are given as a once-weekly injection. A daily oral tablet form of semaglutide was approved in December 2025. If you want the wider picture of how a supervised program is structured before comparing molecules, our explainer on how a GLP-1 weight loss program works covers the sequence of visits and monitoring.
This is the part that gets flattened into "two weight loss shots", and it matters clinically. Wegovy was first approved in June 2021 to reduce excess body weight in adults, extended in December 2022 to patients aged 12 and older with obesity. In March 2024 the FDA approved it to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who also have obesity or overweight. In August 2025 it received accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis, MASH, with moderate to advanced liver fibrosis.
Zepbound was approved in November 2023 for chronic weight management. In December 2024 it became the first prescription medication approved for moderate to severe obstructive sleep apnea in adults with obesity.
So a person with established cardiovascular disease, or with diagnosed sleep apnea, or with MASH, may have a reason to discuss one specific medication that has nothing to do with how many pounds the trials reported. Every one of those approvals is written as a treatment used in combination with a reduced-calorie diet and increased physical activity. That phrasing is in the labeling itself, not an add-on from us.
SURMOUNT-5 is the trial that compared them directly. Its full results were published in the New England Journal of Medicine in 2025. It enrolled 751 adults with obesity who did not have type 2 diabetes, ran for 72 weeks, and compared tirzepatide at maximum tolerated dose, 10 or 15 mg, against semaglutide at maximum tolerated dose, 1.7 or 2.4 mg.
At 72 weeks the tirzepatide group had a mean body weight reduction of 20.2 percent against 13.7 percent in the semaglutide group, a difference the investigators reported as statistically significant. In absolute terms that was 22.8 kg against 15.0 kg. Mean waist circumference fell 18.4 cm against 13.0 cm. Discontinuation because of gastrointestinal side effects was lower on tirzepatide, 2.7 percent, than on semaglutide, 5.6 percent. The trial also reported smaller average reductions among men than among women in both groups.
Read those numbers for what they are. They are group averages at maximum tolerated dose over 72 weeks in people without type 2 diabetes. An average of 20.2 percent contains people who lost considerably more and people who lost considerably less. Diabetes status changes the picture on its own: in the tirzepatide trial program, average reduction at the 15 mg dose was lower among participants who had type 2 diabetes than among those who did not. A trial average is not a forecast for any individual.
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| First FDA approval for weight reduction | June 2021, adults | November 2023, adults |
| Other approved uses | Cardiovascular event risk reduction, 2024; noncirrhotic MASH with moderate to advanced fibrosis, 2025, accelerated approval | Moderate to severe obstructive sleep apnea in adults with obesity, 2024 |
| Same molecule, diabetes brand | Ozempic | Mounjaro |
| How it is taken | Once-weekly injection; a daily oral tablet was approved December 2025 | Once-weekly injection |
| SURMOUNT-5 mean weight change at 72 weeks | Down 13.7 percent | Down 20.2 percent |
| SURMOUNT-5 stopped for gastrointestinal side effects | 5.6 percent of participants | 2.7 percent of participants |
| Boxed warning | Risk of thyroid C-cell tumors | Risk of thyroid C-cell tumors |
The warnings overlap more than the marketing does. Points that appear on both labels:
One asymmetry worth knowing: the Zepbound label lists suicidal behavior and ideation among its warnings and precautions. If you have a history of depression or suicidal thoughts, say so at the evaluation rather than at a later visit.
The head-to-head number is the easiest thing to quote and the least useful thing to decide on alone. Several factors sit above it.
Our medical weight loss program is run by board-certified internal medicine physicians, not by a prescriber you never meet. The sequence is an evaluation first: history, a review of every current prescription, and bloodwork through our on-site laboratory so results come back within the same episode of care rather than weeks later.
Only after that does the question of medication come up, and the first honest answer is sometimes that a GLP-1 based medication is not the right step yet. If it is appropriate, dose changes happen on a monitored schedule at follow-up visits, with side effects reviewed each time. We deliberately do not publish dose schedules: escalation is a clinical decision made for one person, not a chart to follow at home. Our tirzepatide program page describes what is included, and our earlier article on tirzepatide for weight loss in Los Angeles covers the practical side of starting.
When you call, ask which product and formulation the practice dispenses and what the monthly figure covers. That is a fair question to ask any clinic, and a clinic that will not answer it plainly is telling you something.
Elevate Health Group sees patients at three offices: Glendale, Burbank and La Cañada. Weight management visits are available at our offices across the greater Los Angeles area, including Pasadena, Burbank, Glendale and the surrounding foothill communities.
Need Help? Find Answers Here
If you are weighing these medications, the useful next step is an evaluation rather than more reading. Contact our office to arrange a visit in Glendale, Burbank or La Cañada, and bring a list of everything you currently take.
This article is general health information, not medical advice, and reading it does not create a physician-patient relationship. The weight reduction figures quoted are averages from published clinical trials and are not a prediction of any individual result. Individual results vary. Prescription decisions are made by a licensed clinician after an evaluation. Discuss any medication with a qualified clinician before starting or stopping it.

Same-day appointments at our La Cañada office: hours, what gets treated, what is tested on site, and when the emergency room is the right call instead.

Comparing a primary care doctor in Glendale across hospital systems, med-spas, and concierge practices. How access, oversight, and insurance actually differ.
Mon - Fri: 8:00 AM to 12:00 PM, 1:00 PM to 5:00 PM
Sat - Sun: Closed
© 2026 Elevate Health Group. All rights reserved.
Designed & Developed by The Gud Agency